Form 4: Neuronetics Director Glenn Muir Receives RSU Grant

Director Glenn P. Muir was granted 30,000 restricted stock units by Neuronetics, Inc. on May 28, 2026.

Summary

• Director Glenn P. Muir acquired 30,000 restricted stock units (RSUs) of Neuronetics, Inc. (STIM).
• The transaction occurred on May 28, 2026, at a price of $0 per share as part of an equity compensation award.
• Following this transaction, the reporting person's total beneficial ownership of common stock increased to 401,816 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• The grant reflects ongoing commitment from a board member.

Negatives

• The issuance of RSUs results in potential future dilution for existing shareholders upon vesting.

Risks

• Vesting is subject to continuous service requirements through May 28, 2027, or earlier upon specific events like a change in control.

Future Outlook

The RSUs are scheduled to vest on May 28, 2027, or earlier in the event of a board-approved separation of service or a change in control of the company.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to incentivize long-term oversight and alignment with shareholder value in the medical device sector.

Comparison to Industry Standards

• The use of RSU grants for non-employee directors is consistent with standard compensation practices for small-cap medical technology companies.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual vesting and conversion of these RSUs into common stock.

Next Steps

• Vesting of the 30,000 RSUs on May 28, 2027, subject to service conditions.

Key Dates

Keywords

Neuronetics, STIM, Form 4, Insider Trading, Restricted Stock Units, Director Compensation